The compounded semaglutide era effectively ended in 2025. Here's what Hims, Eden, and Mochi pivoted to — and what it costs you now.

You started on Hims compounded semaglutide at $199/mo. Down 22 pounds. Then in early 2025 the email arrived.

"Due to FDA regulatory changes, we are transitioning your treatment plan."

The price went from $199 to $1,899/mo for brand Wegovy.

You're not crazy. The lane you were in didn't exist anymore.

What actually changed: two FDA dates that ended a $200-400 lane

The compounded GLP-1 economy ran on a single legal mechanism: FDA Section 503A and 503B exemptions that allow compounding pharmacies to prepare custom versions of FDA-approved drugs when the brand drug is on the FDA shortage list.

Two dates ended that:

• October 2, 2024 — FDA declared the tirzepatide shortage resolved (Mounjaro / Zepbound).
• February 21, 2025 — FDA declared the semaglutide shortage resolved (Ozempic / Wegovy / Rybelsus).

The Outsourcing Facilities Association (OFA) sued FDA over the tirzepatide decision (OFA v. FDA, N.D. Tex. 4:25-cv-00174). They lost. FDA gave compounders a grace window — 503A pharmacies (state-licensed) until April 22, 2025, and 503B outsourcing facilities until May 22, 2025 — to wind down semaglutide stock. After that, compounding the listed dose strengths of FDA-approved GLP-1s for weight loss became enforcement-eligible.

Translation: the legal cover that let Hims charge you $199 evaporated on a calendar.

What every major telehealth did in response

I went and looked at four companies' homepages this week. Here's the snapshot.

The split is clean. Public companies (Hims is NYSE) don't want SEC disclosure language about "regulatory uncertainty" attached to revenue, so they exit the gray zone fast. Smaller telehealth (Eden, Mochi compounded segment, a tail of independent compounders) operates under "personalized formulation" labels and absorbs the litigation risk in exchange for keeping the $130-300/mo price band alive.

Neither lane is "sketchy" in itself — they're different bets on what the FDA does next. Hims is hedging that enforcement comes; Eden is betting it doesn't, or that the personalization carve-out holds. That gray zone is the part most people don't understand.

"Personalized formulations" — the legal gymnastics that kept some compounding alive

503A pharmacies can still compound a drug if it's not commercially available in a form the patient needs. So compounders pivoted: instead of pure semaglutide (which is now commercially available in five FDA-approved doses), they compound semaglutide with B12, NAD+, glycine, or pyridoxine added — a "personalized formulation" the patient supposedly needs because of unique clinical reasons.

This is the carve-out Eden and a handful of others are running through.

The clinical case for "semaglutide + B12" being meaningfully different from semaglutide alone is thin. The B12 isn't doing pharmacological work for weight loss. The combo exists primarily so the formulation can be defended as not-commercially-available.

FDA has been signaling for a year that they consider many of these combos "essentially copies of commercially available drugs" — which is the regulatory phrase that triggers enforcement. The August 2024 FDA warning letter wave to compounding pharmacies hit this exact formulation strategy.

So if you're on a $199/mo "personalized GLP-1" plan in 2026, you're paying for a formulation that may stop being available on 90 days' notice when FDA escalates. Build that into your month-to-month plan.

The metaphor: it's the moonshine economy

During Prohibition, you didn't shut down because alcohol was illegal. You moved from "saloon selling whiskey" to "soda fountain selling tonic that happens to contain alcohol."

The compounded GLP-1 industry didn't shut down. It moved from "compounding semaglutide" to "compounding personalized peptide formulations." Same molecule, different label, narrower legal lane.

The lane closes when enforcement decides to walk through it. That's a when, not an if.

What $200-400/mo compounded actually was, retrospectively

Most compounded semaglutide came from API sourced through Indian or Chinese peptide manufacturers, shipped to US 503A pharmacies, reconstituted, and dispensed in vials with patient-fillable syringes.

Same upstream API as the generics shipped through licensed personal-import pharmacies.

Different finished-product handling. Different regulatory frame in the US (compounding pharmacy license) versus the personal-import lane (90-day personal supply doctrine).

The $200-400 you were paying covered the US compounding pharmacy markup, telehealth platform fee, and the regulatory compliance overhead of operating under a 503A license.

When that license stopped covering bulk semaglutide for weight loss, the $200-400 had nowhere to land. Either the brand markup absorbs it (now you're paying $349-1,899) or you sit in the personalized-formulation gray zone or you exit US-side entirely.

What Hims is actually selling now, broken down

Hims now lists Wegovy pen at flat $199/mo regardless of dose — the number that replaced the compounded $199. But the structure underneath changed:

• $199/mo for the Wegovy pen, all titration steps and maintenance the same price
• Plus $149/mo membership ("medication is not available without a membership")
• All-in: $199 + $149 = $348/mo at maintenance dose

That's the Hims structure. Worth separating from NovoCare Direct, which is Novo Nordisk's own self-pay brand-direct program — and which uses a tiered structure: $499/mo for 0.25mg-0.5mg titration, ~$349/mo once you settle at 1mg+ maintenance, $149/mo for the Wegovy oral pill. The "$349/mo maintenance bump" people often quote is NovoCare's pricing curve, not Hims's.

So the comparison is: NovoCare Direct gets you to $349/mo at maintenance with no platform/membership fee but you arrange the prescriber yourself. Hims gets you to $348/mo all-in with the prescriber and questionnaire bundled. Roughly the same landed cost; different operational shape.

What you don't see anywhere on the Hims page: the previous compounded option. It's gone.

The current options matrix, cleaned up

If you used to be on $200-400 compounded semaglutide through telehealth, your real choices in April 2026:

The generic personal-import lane LiberaCure routes through is a different legal structure — not a compounding pharmacy license, not an FDA shortage exemption. The 90-day personal-supply lane runs on FDA enforcement-discretion (CPG 9-71-17), in continuous published practice since 1988 — not a statutory legal right, but a posted-policy non-enforcement stance independent of FDA shortage status. It's the same lane that existed before the 2025 crackdown and the same lane that will exist after. The framework is at /honestly.

For reference on our policy: LiberaCure reships once free if tracking shows lost in transit. Second reship also free. Crypto refund (BTC/ETH/USDT) on third failure. Email reply 24-48h ([email protected]). We're not the deepest customer-service operation in this lane — that's where the larger personal-import sites outspend us — but the policy is one screen, not buried in a PDF.

The math on what you actually pay over a year

Assume you respond to semaglutide at maintenance dose and stay on it for 12 months.

• Brand Wegovy via Hims (flat $199/mo + $149 membership × 12) = $4,176/year all-in.
• Brand Wegovy via NovoCare Direct at maintenance ($349/mo × 12) = $4,188/year (no platform fee — but you arrange the prescriber yourself).
• Eden personalized GLP-1 ($129 first month + ~$199/mo × 11 months ongoing) ≈ $2,318/year (assuming the lane stays open all 12 months).
• LiberaCure-routed generic semaglutide injection ($80-150/mo × 12) = $960-1,800/year.

The spread between brand-via-telehealth and personal-import generic is roughly $4,000-5,000 over a single year. For the same active peptide.

The compounded $200-400 lane sat in the middle of that gap. It's now narrower, riskier, and increasingly only available under "personalized" formulations.

What to actually do this month if you got the Hims transition email

1. Don't panic-stop. GLP-1 abrupt discontinuation produces ~67% weight regain within 12 months (STEP-1 extension data). Sudden price jumps are the #1 reason people stop, and the regain math doesn't care why you stopped.

2. Price NovoCare Direct first. The brand-direct self-pay lane is $199-349/mo for the pen. Most people on telehealth-compounded never knew it existed because it wasn't advertised in the telehealth flow. Worth one phone call to NovoCare.

3. Decide on the regulatory lane you want to be in. Brand-direct (FDA-approved, no enforcement risk, $200-500/mo). Personalized-compounded gray zone ($129 first month / ~$199-296/mo ongoing — enforcement risk is real and dated: FDA warning-letter waves hit Aug 2024 and again Q1 2026, so a 12-month exposure window before another wave is realistic). Personal-import generic ($80-150/mo, FDA enforcement-discretion lane independent of US compounding regulation). These are three different structures, not three points on a spectrum — and the right one depends on what you're optimizing for: regulatory certainty, US-side prescriber relationship, or cost.

4. If you choose to compare the personal-import lane: read the Wegovy vs Noveltreat economics breakdown and the GLP-1 comprehensive guide for the full landscape including stopping-and-regain.

5. Before you switch lanes, do not bridge with two weeks of nothing. If you're at maintenance dose 1.7mg or 2.4mg and you skip 4 weeks while you sort out the new supply, you'll lose appetite suppression and start regaining. Get the next month's supply lined up before stopping the current one.

One thing the FDA crackdown didn't do

It didn't make the underlying API harder to source. India remains the largest semaglutide-API exporter on earth, and the molecule is now off-patent in the Indian domestic market as of March 2026 (per CDSCO public approval listings; Novo Nordisk hasn't contested generic launches in India). Patent protection in the US runs through 2031-2033 depending on formulation; that's why brand pricing in the US still sits where it sits.

The crackdown closed the US compounding loophole that let domestic pharmacies legally use shortage-list status to make custom versions. It didn't close the global generic supply or the personal-import lane in any country.

So if your goal was "cheap semaglutide" and you went compounded as a workaround, the 2025 crackdown removed your workaround inside the US. The generic supply abroad is more accessible now than in 2023, not less.

A note on bias.

We route semaglutide orders. Be aware of that.

LiberaCure routes orders to licensed personal-import pharmacies. Sembolic (oral semaglutide, by Torrent Pharma) and Noveltreat (injection pens, by Sun Pharma) are the two semaglutide products we ship in this category — both are global-pharma manufacturers (Sun Pharma is India's #1 by revenue, Torrent is Top-10 with US/EU FDA-inspected facilities), not compounding-pharmacy outputs and not "API-from-anywhere" peptide vendors. Both sit in the personal-import lane, not the US compounding lane — different regulatory structure entirely from what Hims, Eden, or Mochi were operating under, and unaffected by the 2025 FDA shortage decisions.

So we have a financial reason to want this article to lead you toward "the personal-import option exists, here's what it costs."

Read this with that in mind. The protocol above is what I'd tell a friend post-Hims-email, not what maximizes reorder rate. If NovoCare Direct works for you, take NovoCare Direct. If a personalized-compounded plan you trust is keeping your maintenance dose stable at $199/mo, that's a defensible choice too — the regulatory risk on those plans is real but not certain, and "stay where you are until something breaks" is a legitimate strategy.

Sources:

• FDA Drug Shortages Database. Tirzepatide (Mounjaro / Zepbound) shortage resolved October 2, 2024. Semaglutide (Ozempic / Wegovy / Rybelsus) shortage resolved February 21, 2025. 503A grace period through April 22, 2025; 503B through May 22, 2025.
• Outsourcing Facilities Association (OFA) v. FDA, US District Court for the Northern District of Texas, Case No. 4:25-cv-00174 (tirzepatide enforcement delay litigation).
• FDA Section 503A and 503B compounding regulations; FDA warning letters to compounding pharmacies on "essentially copies" doctrine, August 2024 wave.
• Hims & Hers Health, Inc. publicly disclosed transition from compounded GLP-1 to brand-only, late 2024 / early 2025 (10-Q and shareholder communications).
• Hims weight-loss page pricing, accessed April 28, 2026: Wegovy pen flat $199/mo regardless of dose + mandatory $149/mo membership ($348 all-in); Mounjaro/Zepbound $1,899/mo.
• Eden weight-loss page, accessed April 28, 2026: "Personalized GLP-1 treatments from $129 first month, ~$199/mo ongoing."
• NovoCare Direct self-pay program, accessed April 28, 2026: tiered Wegovy pen pricing ($499/mo titration / ~$349/mo at maintenance), $149/mo for Wegovy oral pill.
• FDA Compliance Policy Guide 9-71-17 (Coverage of Personal Importations) — establishes the enforcement-discretion stance that underpins the 90-day personal-supply lane; published 1988, in continuous practice since.
• Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24(8):1553-1564. PMID 35441470

— LiberaCure editorial. We route generic medication through licensed personal-import pharmacies. We don't dispense, prescribe, or warehouse. Read more about why.